A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatment.
Lead PI: Professor Vincent Thijs
Participating Australian and New Zealand Sites: Austin Health, Alfred Health, CGM Research Trust
Status: ASTN endorsed, Site selection, Recruiting
No. of Patients Currently Recruited: 40 No. of Patients Required: 168
All three sites are actively recruiting patients. Site target goal is to recruit 1 patient per week to help meet recruitment target of 168 total. Other advertising/recruitment strategies are also being explored in parallel, to help boost and keep recruitment momentum.